6. Parkinson disease
2,123 clinical trials,   2,046 drugs   (DrugBank: 324 drugs),   183 drug target genes,   198 drug target pathways
Searched query = "Parkinson disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04070495 (ClinicalTrials.gov) | August 27, 2019 | 26/8/2019 | A Drug Interaction Study of KW-6356 and Clarithromycin or Rifampicin | A Drug Interaction Study of KW-6356 and Clarithromycin or Rifampicin (A Drug Interaction Study With a CYP3A4/5 Inhibitor or Inducer) | Parkinson's Disease | Drug: KW-6356;Drug: Clarithromycin;Drug: Rifampicin | Kyowa Kirin Co., Ltd. | NULL | Completed | 20 Years | 44 Years | Male | 20 | Phase 1 | Japan |
2 | NCT03440112 (ClinicalTrials.gov) | January 29, 2018 | 26/1/2018 | Modulation of GABA-A Receptors in Parkinson Disease-Transdermal Flumazenil Arm | Modulation of GABA-A Receptors and Axial Motor Impairments in Parkinson | Parkinson Disease | Drug: Clarithromycin (Not used as of 4/2020);Drug: Placebo (Not used as of 4/2020);Drug: Transdermal flumazenil (Added 4/2020);Drug: Placebo (Added 4/2020) | Nicolaas Bohnen, MD, PhD | National Institute of Neurological Disorders and Stroke (NINDS) | Recruiting | 50 Years | N/A | All | 30 | Phase 1;Phase 2 | United States |